2005Yiyao daobaoRequires access

Inhibitory Effects of Cyclooxygenase-2 Inhibitory Drugs on Human Osteosarcoma and Lung Cancer Cell Lines

Fang-Zhou Chen

Open publisher page 0 citations

Abstract

Objective To compare the effects of two cyclooxygenase-2 inhibitors,celecoxib and rofecoxib on the growth of human osteosarcoma (HOS-8603) and lung cancer cell (A-549) lines. Methods The anti-proliferation effects were determined by methabenzthiazuron (MTT) method. The cell growing cycle and the cell apoptosis were analyzed by flow cytometry. Results Cyclooxygenase-2 inhibitors, celecoxib and rofecoxib had inhibitory and apoptosis-inducting effect on the growth of the two tumor cell lines. The inhibitions of celecoxib and rofecoxib to the two tumor cell lines were dose-dependent and time-dependent. The cells treated with the two drugs showed a G_2/M arrest which was the peak time of apoptosis. There was a significant difference between rofecoxib and celecoxib groups ( P 0.05). And celecoxib had a stronger inhibition to HOS-8603 than rofecoxib. Conclusion Cyclooxygenase-2 inhibitors, celecoxib and rofecoxib have significant effect on the growth of the two tumor cell lines, and may become useful medicines in tumor treatment.

About this research paper

What this paper is about

Objective To compare the effects of two cyclooxygenase-2 inhibitors,celecoxib and rofecoxib on the growth of human osteosarcoma (HOS-8603) and lung cancer cell (A-549) lines. Methods The anti-proliferation effects were determined by methabenzthiazuron (MTT) method. The cell growing cycle and the cell apoptosis were analyzed by flow cytometry. Results Cyclooxygenase-2 inhibitors, celecoxib and rofecoxib had inhibitory and apoptosis-inducting effect on the growth of the two tumor cell lines. The inhibitions of celecoxib and rofecoxib to the two tumor cell lines were dose-dependent and time-dependent. The cells treated with the two drugs showed a G_2/M arrest which was the peak time of apoptosis. There was a significant difference between rofecoxib and celecoxib groups ( P 0.05). And celecoxib had a stronger inhibition to HOS-8603 than rofecoxib. Conclusion Cyclooxygenase-2 inhibitors, celecoxib and rofecoxib have significant effect on the growth of the two tumor cell lines, and may become useful medicines in tumor treatment.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To compare the effects of two cyclooxygenase-2 inhibitors,celecoxib and rofecoxib on the growth of human osteosarcoma (HOS-8603) and lung cancer cell (A-549) lines. Methods The anti-proliferation effects were determined by methabenzthiazuron (MTT) method. The cell growing cycle and the cell apoptosis were analyzed by flow cytometry. Results Cyclooxygenase-2 inhibitors, celecoxib and rofecoxib had inhibitory and apoptosis-inducting effect on the growth of the two tumor cell lines. The inhibitions of celecoxib and rofecoxib to the two tumor cell lines were dose-dependent and time-dependent. The cells treated with the two drugs showed a G_2/M arrest which was the peak time of apoptosis. There was a significant difference between rofecoxib and celecoxib groups ( P 0.05). And celecoxib had a stronger inhibition to HOS-8603 than rofecoxib. Conclusion Cyclooxygenase-2 inhibitors, celecoxib and rofecoxib have significant effect on the growth of the two tumor cell lines, and may become useful medicines in tumor treatment.

Key concepts: Rofecoxib, Celecoxib, Cyclooxygenase, Apoptosis, Pharmacology, Cell growth, Medicine, Cell culture

Related papers

Back to paper searchBrowse research topicsOriginal source
Inhibitory Effects of Cyclooxygenase-2 Inhibitory Drugs on Human Osteosarcoma and Lung Cancer Cell Lines — Research Paper | ScholarLens